Last reviewed · How we verify
Prevention of stroke
Approved treatments
- Dabigatran etexilate (DE) · Pfizer Inc.
Dabigatran etexilate (DE) as oral capsule - Pradaxa · Boehringer Ingelheim
Competitive direct thrombin inhibitor preventing fibrin formation and thrombus development. - Pradaxa · Generic (originally Boehringer Ingelheim)
Direct thrombin inhibitor that blocks both free and clot-bound thrombin, providing anticoagulation without routine monitoring.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prevention of stroke patent landscape — cliff calendar, originator estates, attackable patents
- Prevention of stroke treatment landscape brief
- Prevention of stroke treatment updates RSS
Frequently asked questions about Prevention of stroke
What drugs treat Prevention of stroke?
Tracked treatments include Dabigatran etexilate (DE), Pradaxa.
What is the treatment for Prevention of stroke?
Standard treatment for Prevention of stroke includes Dabigatran etexilate (DE), Pradaxa. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prevention of stroke patent cliff · Prevention of stroke CI report
- Treatment: Dabigatran etexilate (DE) · Pfizer Inc.
- Treatment: Pradaxa · Boehringer Ingelheim
- Treatment: Pradaxa · Generic (originally Boehringer Ingelheim)
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing